Tempus expands multi-year collaboration with Gilead for oncology research
Go back to Tempus expands multi-year collaboration with Gilead for oncology research| Gilead Sciences (NASDAQ: GILD) | Delayed: 130.86 +0.52 (0.40%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $130.34 | 52 Week High | $108.63 | |||
| Open | $129.22 | 52 Week Low | $71.39 | |||
| Day High | $131.07 | P/E | 72.30 | |||
| Day Low | $127.61 | EPS | $1.81 | |||
| Volume | 6,299,362 | |||||
| StemCells, Inc. (NASDAQ: TEM) | Delayed: 46.01 -0.95 (2.02%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $46.96 | 52 Week High | $0.45 | |||
| Open | $46.10 | 52 Week Low | $0.37 | |||
| Day High | $47.54 | P/E | N/A | |||
| Day Low | $45.51 | EPS | $-0.31 | |||
| Volume | 4,474,913 | |||||
